Ocular Therapeutix, Inc. $OCUL Shares Bought by E. Ohman J or Asset Management AB

E. Ohman J or Asset Management AB lifted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 28.3% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 385,000 shares of the biopharmaceutical company’s stock after acquiring an additional 85,000 shares during the quarter. E. Ohman J or Asset Management AB’s holdings in Ocular Therapeutix were worth $3,781,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of OCUL. Empire Life Investments Inc. raised its position in shares of Ocular Therapeutix by 115.0% during the fourth quarter. Empire Life Investments Inc. now owns 540,115 shares of the biopharmaceutical company’s stock worth $6,557,000 after purchasing an additional 288,853 shares during the period. Candriam S.C.A. boosted its position in shares of Ocular Therapeutix by 12.8% in the 1st quarter. Candriam S.C.A. now owns 949,216 shares of the biopharmaceutical company’s stock valued at $8,040,000 after purchasing an additional 107,614 shares during the period. Octagon Capital Advisors LP boosted its position in shares of Ocular Therapeutix by 20.7% in the 1st quarter. Octagon Capital Advisors LP now owns 3,166,600 shares of the biopharmaceutical company’s stock valued at $26,821,000 after purchasing an additional 543,000 shares during the period. Prescott Group Capital Management L.L.C. purchased a new position in Ocular Therapeutix in the 4th quarter worth about $3,800,000. Finally, Commodore Capital LP acquired a new stake in Ocular Therapeutix during the 1st quarter worth about $21,810,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Stock Performance

Shares of NASDAQ OCUL opened at $9.24 on Tuesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 13.10 and a quick ratio of 13.03. Ocular Therapeutix, Inc. has a one year low of $6.23 and a one year high of $16.44. The business’s 50-day moving average price is $9.16 and its two-hundred day moving average price is $9.08. The company has a market capitalization of $2.03 billion, a P/E ratio of -6.51 and a beta of 0.93.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.05. The firm had revenue of $13.47 million for the quarter, compared to the consensus estimate of $13.20 million. Ocular Therapeutix had a negative return on equity of 59.89% and a negative net margin of 579.10%.The firm’s revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.39) earnings per share. Analysts anticipate that Ocular Therapeutix, Inc. will post -1.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Chardan Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, August 4th. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday. HC Wainwright restated a “buy” rating and set a $25.00 price target (up from $21.00) on shares of Ocular Therapeutix in a report on Thursday, June 18th. Royal Bank Of Canada restated an “outperform” rating and issued a $30.00 price target on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $18.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Eleven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.75.

Insider Activity at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,156 shares of the firm’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $173,479.20. Following the transaction, the insider owned 2,597,170 shares in the company, valued at approximately $21,296,794. This trade represents a 0.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 28,999 shares of company stock worth $237,792. Corporate insiders own 3.10% of the company’s stock.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.